ARA-290 (Cibinetide) (10mg)

Non-erythropoietic erythropoietin-derived peptide. ARA-290 is an 11-amino-acid peptide patterned on the helix B surface of erythropoietin. It switches on the tissue-protective innate repair receptor while leaving the classical erythropoietin receptor alone, so red-cell mass does not rise. That separation is the entire reason the molecule exists.

Small-fibre neuropathy: corneal confocal microscopy endpoints. Innate repair receptor: selective activation that spares erythropoiesis. Metabolic research: hbA1c and lipid changes in diabetic cohorts. Tissue protection: models of kidney and cardiac ischaemia. In Phase 2 trials for sarcoidosis-associated small-fibre neuropathy (Dahan et al., Mol Med 2013; Culver et al., Front Neurol 2017), corneal nerve-fibre density improved and neuropathic symptoms eased. Diabetic neuropathy and metabolic endpoints have likewise been studied.

Phase 2 trials in sarcoidosis small-fibre neuropathy reported higher corneal nerve-fibre density and lower neuropathic symptom scores across 28 days; in a diabetic cohort, HbA1c and lipids improved alongside the neuropathy measures.

Trials reported tolerability on a par with placebo and no erythropoietic effects, which is the molecule's purpose. Data beyond the trial durations are limited.

The published ARA-290 (Cibinetide) abstracts we cite do not state the amounts used, so there is no study figure to report. Peptide Aus supplies ARA-290 (Cibinetide) for in-vitro laboratory research and does not give dosing, cycle or usage guidance for people. The reconstitution section on this page covers how the vial is prepared.

ARA-290 retains EPO's tissue-protective receptor activity while dropping the red-cell effect.

Add about 2 mL of bacteriostatic water slowly down the inside of the vial and swirl gently; do not shake. 10mg in 2 mL gives 5 mg/mL. Refrigerate at 2–8 °C after reconstitution and use within 8–12 weeks. The calculator has this vial preset.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

The Therapeutic Goods Administration (TGA) has not registered ARA-290 (Cibinetide) as a medicine in Australia, and it is not approved for human or veterinary use. Peptide Aus supplies it only as a research reagent for in-vitro laboratory work. In Australia the supply of any substance for human use is governed by the Poisons Standard and the Therapeutic Goods Act, and lawful use is the buyer's responsibility. If you are after a treatment, speak to a doctor.

Directly from Peptide Aus, from Australian stock: ARA-290 (Cibinetide) (10mg) is $89.99 AUD including GST. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.